MENU Hamburger icon X

17 million
people experience early AMD1

Here’s how our latest
formula can help
support them.

22%

lower risk of neovascular AMD8

25%
risk reduction in moderate-to-advanced AMD7
B Vitamins

Support cellular metabolism and healthy homocysteine levels2*

AREDS2 Nutrients

NEI-recommended nutrients help reduce the
risk of AMD progression5,6*†

Supports
the body’s natural response to oxidative stress2*

42%

reduced risk of early AMD4

41%

reduced risk of visually significant AMD3

B Vitamins

Support cellular metabolism and healthy homocysteine levels2*

41%

reduced risk of visually
significant AMD3

42%

reduced risk of early AMD4

B Vitamins +
AREDS2 Nutrients

Supports the body’s natural response to oxidative stress2*

AREDS2 Nutrients

NEI-recommended nutrients help reduce the risk of AMD progression5,6*†

25%

risk reduction in moderate-to-advanced AMD7

22%

lower risk of neovascular AMD8

Evidence suggests that B vitamins and AREDS2 nutrients both support eye health and help reduce the risk of AMD. B vitamins support cellular metabolism and help maintain healthy homocysteine levels2*. They are associated with a 41% reduced risk of visually significant AMD3 and a 42% reduced risk of early AMD4. AREDS2 NEI-recommended nutrients help reduce the risk of AMD progression5,6†, including a 25% risk reduction in moderate-to-advanced AMD7 and a 22% lower risk of neovascular AMD8. Together, B vitamins and AREDS2 nutrients support the body’s natural response to oxidative stress2*.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†In moderate-to-advanced AMD patients.

Multiple Studies Support the Role
of
B Vitamins in Reducing Incidence
and
Progression
of AMD

These study outcomes helped inform the ingredient profile for the AREDS3 formulation.

Nutrient
Dietary Intake
Risk Level
B1
↑
↓ by ~45-60%9 for late AMD
B6
↑
↓ for wet AMD10
B9
↑
↓ for developing GA and
large drusen10,4
B12
↑
↓ for AMD by 42%4
B5, B6
↑
↓ by ~28% for advanced AMD4
B6, B9
↑
↓ for late AMD10
B1, B2, B3, B5,
B6, B9, B12
↓
Observed in patients with
AMD vs without AMD11,12
Daily Supplement
B2 + 13 other ingredients
Stabilized
atrophic AMD13,14
B3 + 2 other ingredients
Improved a measure of retinal function (FERG)15
B12 + 11 other ingredients
Functional improvement
of preganglionic
retinal elements16
B6, B9, B12
↓ risk of AMD vs
placebo by ~41%3
Nutrient
B1
Dietary Intake: ↑
Risk Level: ↓ by ~45-60%9 for late AMD
B6
Dietary Intake: ↑
Risk Level: ↓ for wet AMD10
B9
Dietary Intake: ↑
Risk Level: ↓ for developing GA and large drusen10,4
B12
Dietary Intake: ↑
Risk Level: ↓ for AMD by 42%4
B5, B6
Dietary Intake: ↑
Risk Level: ↓ by ~28% for advanced AMD4
B6, B9
Dietary Intake: ↑
Risk Level: ↓ for late AMD10
B1, B2, B3, B5, B6, B9, B12
Dietary Intake: ↓
Risk Level: Observed in patients with AMD vs without AMD11,12
Daily Supplement
B2 + 13 other ingredients
Stabilized atrophic AMD13,14
B3 + 2 other ingredients
Improved a measure of retinal function (FERG)15
B12 + 11 other ingredients
Functional improvement of preganglionic retinal elements16
B6, B9, B12
↓ risk of AMD vs placebo by ~41%3
An upward arrow (↑) indicates increased dietary intake or higher nutrient levels, while a downward arrow (↓) indicates a reduction in risk, incidence, or progression of AMD.

Select B-vitamin supplementation may
help reduce
homocysteine,
a
modifiable AMD risk factor3

The AREDS3 Formulation

Our next-gen formula combines AREDS 2 nutrients with a
B-vitamin complex.

Nutrient
AREDS2
AREDS3
Lutein
10 mg
10 mg
Zeaxanthin
2 mg
2 mg
Vitamin C
500 mg
500 mg
Vitamin E
180 mg
180 mg
Zinc
80 mg
25 mg
Copper
2 mg
2 mg
Thiamin (Vitamin B1)
—
3.6 mg
Riboflavin (Vitamin B2)
—
3.9 mg
Niacin (Vitamin B3)
—
32 mg
Pantothenic Acid (Vitamin B5)
—
15 mg
Vitamin B6
—
50 mg
Biotin (Vitamin B7)
—
90 mcg
Folate (Vitamin B9)
—
1500 mcg DFE
(900 mcg folic acid)
Vitamin B12
—
1000 mcg
areds3_icon1

AREDS3 retains the same evidence-based nutrients of AREDS2: vitamin C, vitamin E, lutein, zeaxanthin, copper, and zinc

areds3_icon1

B vitamins were added to the formula for metabolic support: homocysteine, mitochondrial function, and vascular health

areds3_icon1

Take 1 Soft Gel with a meal
2 times per day

Nutrient
Lutein
AREDS2: 10 mg
AREDS3: 10 mg
Zeaxanthin
AREDS2: 2 mg
AREDS3: 2 mg
Vitamin C
AREDS2: 500 mg
AREDS3: 500 mg
Vitamin E
AREDS2: 180 mg
AREDS3: 180 mg
Zinc
AREDS2: 80 mg
AREDS3: 25 mg
Copper
AREDS2: 2 mg
AREDS3: 2 mg
Thiamin (Vitamin B1)
AREDS2: —
AREDS3: 3.6 mg
Riboflavin (Vitamin B2)
AREDS2: —
AREDS3: 3.9 mg
Niacin (Vitamin B3)
AREDS2: —
AREDS3: 32 mg
Pantothenic Acid (Vitamin B5)
AREDS2: —
AREDS3: 15 mg
Vitamin B6
AREDS2: —
AREDS3: 50 mg
Biotin (Vitamin B7)
AREDS2: —
AREDS3: 90 mcg
Folate (Vitamin B9)
AREDS2: —
AREDS3: 1500 mcg DFE
(900 mcg folic acid)
Vitamin B12
AREDS2: —
AREDS3: 1000 mcg
areds3_icon1

AREDS3 retains the same
evidence-based nutrients of
AREDS2: vitamin C, vitamin E,
lutein, zeaxanthin, copper, and
zinc

areds3_icon1

B vitamins were added to the
formula for metabolic
support: homocysteine,
mitochondrial function, and
vascular health

areds3_icon1

Take 1 Soft Gel with a meal
2 times per day

union_icon

Review the Latest
Article on
the Role of B Vitamins
in AMD Progression.

See the Sciencedownload
chart_icon

The PreserVision® AREDS3
formula
will be studied in
a long-term
trial, including
people with all
stages of
AMD, from early to

geographic atrophy.

AMD = age-related macular degeneration
AREDS = age-related eye disease study
NEI = National Eye Institute

REFERENCES: 1. Circana. Bausch + Lomb Consumer Data Science. Total US panel L52WE Oct 5, 2025. IQVIA. Bausch + Lomb Consumer Data Science. Total US study—size of AMD. November 2024. 2. Poteet J et al. Ophthalmol Ther. 2025. 3. Christen WG et al. Arch Intern Med. 2009;169:335-341. 4. Merle BMJ et al. Nutrients. 2022;14(14):2821. 5. Age-Related Eye Disease Study Research Group. Arch Ophthalmol. 2001;119(10):1417-1436. 6. Chew EY et al. Ophthalmology. 2012;119(11):2282-2289. 7. Chew EY et al. JAMA Ophthalmol. 2022;140(7):692-698. 8. Age-Related Eye Disease Study 2 (AREDS2) Research Group. JAMA. 2013;309(19):2005-2015. 9. Zheng Q et al. Ophthalmic Res. 2023;66:1353-1361. 10. Agrón E et al. Ophthalmology. 2021;128:425-442. 11. Šalková Kráľová J et al. Cent Eur J Public Health. 2023;31:140-143. 12. Liu Z et al. Front Nutr. 2024;11:1504081. 13. Age-Related Macular Degeneration Study Group. J Am Optom Assoc. 1996;67:12-29. 14. Richer S. J Am Optom Assoc. 1996;67:30-49. 15. Falsini B et al. Ophthalmology. 2003;110:51-60. 16. Parravano M et al. Adv Ther. 2019;36:2493-2505.

Text Size:A−A+